First Clinical Use of SetPoint® System for Rheumatoid Arthritis in the Pacific Northwest
In a significant advancement, Oregon Health & Science University (OHSU) has become the first healthcare facility in the Pacific Northwest to employ the SetPoint® System, a groundbreaking treatment for patients suffering from rheumatoid arthritis (RA). This system marks the only FDA-approved method employing neuroimmune modulation therapy in the United States specifically designed for adults experiencing moderately to severely active RA.
Rheumatoid arthritis is a debilitating auto-immune disease characterized by the immune system's attack on the joint lining, leading to pain, swelling, and eventual joint damage. Approximately 1.5 million adults in the U.S. are currently impacted by this condition. Despite improvements in medical treatments over the last twenty years, many RA patients still endure inadequately controlled symptoms or struggle with the side effects of existing therapies, highlighting the urgent need for alternative solutions.
The SetPoint System provides such an alternative. It includes a small, implantable neurostimulator that focuses on targeting the left vagus nerve. When activated, this device stimulates the body's natural anti-inflammatory pathways, effectively regulating the immune responses tied to RA.
Patients benefit from a unique setup, charging the device at home with a wireless charger comfortably worn around the neck for just a few minutes each week. "We are dedicated to expanding access to innovative treatments that can revolutionize how we manage complex conditions like rheumatoid arthritis," stated Ahmed M. Raslan, M.D., who chairs the Neurological Surgery department at OHSU.
OHSU's commitment to clinical excellence and the adoption of cutting-edge treatments positions it at the forefront of rheumatoid arthritis care. Murthy Simhambhatla, CEO of SetPoint Medical, expressed gratitude for the opportunity to collaborate with such a renowned institution, aiming to broaden the spectrum of available therapies in Oregon and the greater Pacific Northwest.
The introduction of the SetPoint System is expected to significantly enhance the quality of life for patients who do not respond favorably to traditional biological or targeted synthetics that are typically used to manage RA. With the system now implemented at OHSU, patients in the region can look forward to a renewed sense of hope in their treatment pathways.
But what exactly is the SetPoint® System designed for? This therapy is expressly indicated for adult individuals with RA who have faced inadequate treatment responses or have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs), which can include both biologics and targeted therapies.
Risks associated with this treatment may include, but are not limited to, post-surgery pain or infection, hoarseness, bruising, swelling, and throat irritation. However, when weighed against the chronic pain and debilitating effects of rheumatoid arthritis, many patients and their healthcare providers see it as a valuable option.
SetPoint Medical, known for its focus on chronic autoimmune disease care, is excited to expand this innovative technology's reach. Plans are also being laid out for exploring the application of this neurostimulation platform for treating other autoimmune conditions, such as multiple sclerosis and Crohn's disease, anticipating a shift in the management of chronic illnesses.
As the SetPoint System gains traction, it enhances the accessibility of advanced medical technology for RA patients across the United States, reducing the immeasurable burden that this chronic disease places on countless individuals and their families. With OHSU leading the charge in the Pacific Northwest, this is just the beginning of a new era of care for people living with rheumatoid arthritis.
Rheumatoid arthritis is a debilitating auto-immune disease characterized by the immune system's attack on the joint lining, leading to pain, swelling, and eventual joint damage. Approximately 1.5 million adults in the U.S. are currently impacted by this condition. Despite improvements in medical treatments over the last twenty years, many RA patients still endure inadequately controlled symptoms or struggle with the side effects of existing therapies, highlighting the urgent need for alternative solutions.
The SetPoint System provides such an alternative. It includes a small, implantable neurostimulator that focuses on targeting the left vagus nerve. When activated, this device stimulates the body's natural anti-inflammatory pathways, effectively regulating the immune responses tied to RA.
Patients benefit from a unique setup, charging the device at home with a wireless charger comfortably worn around the neck for just a few minutes each week. "We are dedicated to expanding access to innovative treatments that can revolutionize how we manage complex conditions like rheumatoid arthritis," stated Ahmed M. Raslan, M.D., who chairs the Neurological Surgery department at OHSU.
OHSU's commitment to clinical excellence and the adoption of cutting-edge treatments positions it at the forefront of rheumatoid arthritis care. Murthy Simhambhatla, CEO of SetPoint Medical, expressed gratitude for the opportunity to collaborate with such a renowned institution, aiming to broaden the spectrum of available therapies in Oregon and the greater Pacific Northwest.
The introduction of the SetPoint System is expected to significantly enhance the quality of life for patients who do not respond favorably to traditional biological or targeted synthetics that are typically used to manage RA. With the system now implemented at OHSU, patients in the region can look forward to a renewed sense of hope in their treatment pathways.
But what exactly is the SetPoint® System designed for? This therapy is expressly indicated for adult individuals with RA who have faced inadequate treatment responses or have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs), which can include both biologics and targeted therapies.
Risks associated with this treatment may include, but are not limited to, post-surgery pain or infection, hoarseness, bruising, swelling, and throat irritation. However, when weighed against the chronic pain and debilitating effects of rheumatoid arthritis, many patients and their healthcare providers see it as a valuable option.
SetPoint Medical, known for its focus on chronic autoimmune disease care, is excited to expand this innovative technology's reach. Plans are also being laid out for exploring the application of this neurostimulation platform for treating other autoimmune conditions, such as multiple sclerosis and Crohn's disease, anticipating a shift in the management of chronic illnesses.
As the SetPoint System gains traction, it enhances the accessibility of advanced medical technology for RA patients across the United States, reducing the immeasurable burden that this chronic disease places on countless individuals and their families. With OHSU leading the charge in the Pacific Northwest, this is just the beginning of a new era of care for people living with rheumatoid arthritis.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.